Supplementary Figures S1 through S10 from Characterization of MK-4166, a Clinical Agonistic Antibody That Targets Human GITR and Inhibits the Generation and Suppressive Effects of T Regulatory Cells

Supplementary Figure S1 shows the gating scheme and markers used to phenotype various T cell subsets in human blood. Supplementary Figure S2 shows the expression of GITR on human and cynomolgus monkey NK cells and T cells. Supplementary Figure S3 shows the expression of GITR on various human tumor infiltrating T cell subsets. Supplementary Figure S4 shows the phenotypic and functional characterization of CD4+ CD25+ TILs from NSCLC tumor tissues. Supplementary Figure S5 shows the phenotypic and functional characterization of iTregs generated in MLR cultures. Supplementary Figure S6 shows the differential effects of MK-4166 when added to MLR cultures on Day 0 vs Day 7. Supplementary Figure S7 shows the potential of MK-4166 to induce ADCC when bound to human iTregs. Supplementary Figure S8 shows the attenuation of nTreg suppression by MK-4166. Supplementary Figure S9 shows the purity of enriched nTregs used in Treg suppression assays. Supplementary Figure S10 shows the effect of MK-4166 on nTreg proliferation.